CJC-1295 vs PE-22-28
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | PE-22-28 |
|---|---|---|
| Dose Range | 1 mg–2 mg | 500 mcg–2 mg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 8–12 weeks | 1–2 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Very limited human data. Primarily studied in animal models for safety and efficacy. |
| Best For |
Key Differences
Unique to CJC-1295:
Unique to PE-22-28:
Key Studies
CJC-1295
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Drug testing and analysis, 2019
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Drug testing and analysis, 2019
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse, 2016
Ready to Learn More?
Looking for trusted sources?